title: Determination of urinary 18-hydroxycortisol in the diagnosis of primary aldosteronism.
abstract: Urinary excretion of 18-hydroxycortisol (18-OHF), 18-hydroxycorticosterone (18-OHB) and aldosterone 18-glucuronide (Aldo-18-glu) was measured in 10 patients with primary aldosteronism; 5 with aldosterone-producing adenoma (APA) and 5 with idiopathic hyperaldosteronism (IHA), 10 patients with essential hypertension (EHT) and 11 normotensive subjects. In EHT patients, urinary 18-OHF (172 +/- 15 micrograms/24h) and 18-OHB (3.1 +/- 0.6 micrograms/24h) values were not significantly different from 18-OHF (142 +/- 35 micrograms/24h) and 18-OHB (3.6 +/- 0.5 micrograms/24h) in the controls. Urinary 18-OHF values were significantly higher in APA (640 +/- 213 micrograms/24h) when compared with controls and EHT, whereas 18-OHB (11.3 +/- 1.5 micrograms/24h) values were only slightly elevated. Both 18-OHF and 18-OHB were significantly increased in APA compared with 18-OHF (232 +/- 56 micrograms/24h) and 18-OHB (4.6 +/- 0.3 micrograms/24h) in IHA. The two urinary steroids, especially 18-OHF proved to be a useful marker for the diagnosis of APA, confirming the previous findings. Aldo-18-glu was not significantly different between APA and IHA. In normal subjects when sodium intake was restricted to 48meq/day for four days the urinary 18-OHF was increased two fold to 383 +/- 59 micrograms/24h (p less than 0.01 vs control period) associated with comparable rise in plasma renin activity. This suggests that the biosynthesis of 18-OHF is partly under control of renin-angiotensin axis in normal subjects.
authors.affiliation: Second Department of Internal Medicine, Kanazawa University, Japan.
authors.forename: I
authors.initials: I
authors.lastname: Miyamori
authors.forename: Y
authors.initials: Y
authors.lastname: Takeda
authors.forename: H
authors.initials: H
authors.lastname: Takasaki
authors.forename: Y
authors.initials: Y
authors.lastname: Itoh
authors.forename: K
authors.initials: K
authors.lastname: Iki
authors.forename: R
authors.initials: R
authors.lastname: Takeda
mesh_terms: D015069:18-Hydroxycorticosterone / Q000652:urine; D000236:Adenoma / Q000175:diagnosis / Q000378:metabolism / Q000652:urine; D000302:Adrenal Cortex / Q000187:drug effects / Q000502:physiology; D000306:Adrenal Cortex Neoplasms / Q000175:diagnosis / Q000378:metabolism / Q000652:urine; D000450:Aldosterone / Q000378:metabolism; D003937:Diagnosis, Differential; D005260:Female; D005965:Glucuronates / Q000652:urine; D006801:Humans; D006854:Hydrocortisone / Q000031:analogs & derivatives* / Q000652:urine; D006929:Hyperaldosteronism / Q000175:diagnosis* / Q000652:urine*; D006973:Hypertension / Q000175:diagnosis / Q000652:urine; D008297:Male; D008875:Middle Aged; D012964:Sodium / Q000494:pharmacology
chemical_list: D005965:Glucuronates; D000450:Aldosterone; D015069:18-Hydroxycorticosterone; D012964:Sodium; C033689:18-hydroxycortisol; D006854:Hydrocortisone